Harvard Bioscience: HBIO stock stalls, margin pressure in focus
Harvard Bioscience closed at $5.59 Friday, up 1.3% for the day and 6.5% for the week, following a 1-for-10 reverse stock split in March. First-quarter revenue fell to $20.8 million, with a net loss of $3.4 million and gross margin rising to 59%. The company cited weak demand from academic and distributor customers and faces a 17.3% effective interest rate on borrowings. CEO John Duke and CFO Mark Frost will speak at a virtual conference May 28.